Please upgrade to a new Web browser for best viewing this site!

Department of
Therapeutic Radiology
Yale University
School of Medicine
P.O. Box 208040
New Haven, CT 06520-8040

Resident Staff

Residents in the Department of Therapeutic Radiology are offered a comprehensive clinical and research training experience. Trainees are presented with a vast range of research opportunities and are encouraged to pursue clinical and/or ‘translational’ investigation during the training period. The Yale faculty and program provide an enriched core of mentors and infrastructure that enable residents to bring such projects to fruition. The following is a list of the current resident trainees and selected resident publications beginning with the graduating class of 2005.

2008 NRMP Results
We would like to welcome Thomas Klein, MD, PhD (Mt. Sinai School of Medicine) and Kimberly Johung, MD, PhD (Yale School of Medicine) who will both be joining our residency program in July of 2009.

PGY-1

PGY-2

PGY-3

PGY-4

PGY–5

Selected Resident Publications (Peer-Reviewed)

  1. Phillips GN, Teodoro ML, Li T, Smith B, Olson JS: Bound CO is a molecular probe of electrostatic potential in the distal pocket of myoglobin. Journal of Physical Chemistry B 103:8817-8829, 1999
  2. Smith BD, Haffty BG: Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiation Oncology Investigations 7:125-144, 1999
  3. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG: The prognostic utility of VEGF protein levels in oral and oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology 18:2046-2052, 2000
  4. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, Haffty BG: Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Archives of Otolaryngology-Head & Neck Surgery 127:780-785, 2001
  5. Smith BD, Haffty BG, Sasaki CT: Molecular markers in head and neck squamous cell carcinoma: their biologic function and prognostic significance. Annals of Otology, Rhinology, and Laryngology 110:221-228, 2001
  6. Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, Haffty BG: Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clinical Cancer Research 8:540-548, 2002
  7. Smith BD, Wilson LD: Disseminated herpes simplex after total skin electron beam radiotherapy for mycosis fungoides. Journal of the Royal Society of Medicine 96:500-501, 2003
  8. Smith BD, Wilson LD: Management of Mycosis Fungoides: Part 1. Diagnosis, Staging, and Prognosis. Oncology (Huntington) 17:1281-1288, 2003
  9. Smith BD, Wilson LD: Management of Mycosis Fungoides: Part II. Treatment. Oncology (Huntington) 17:1419-1428, 2003
  10. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD: Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the World Health Organization classification systems. Journal of Clinical Oncology 22:634-639, 2004
  11. Smith BD, Esfahanian S, Dhami MS, Fischer JJ: Isolated needle-track recurrence following fine needle aspiration for non-small cell lung cancer. Journal of Clinical Oncology, 22:3828-3829, 2004
  12. Smith BD, Smith GL, Haffty BG. Post-mastectomy radiation and survival in women with T1-2 N+ breast cancer. Journal of Clinical Oncology, 23:1409-1419, 2005
  13. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. Journal of Clinical Oncology 23:3390-3395, 2005.
  14. Floyd SR, Pantanowitz L, McDermott DF, Yannucci J, Driver JA, Stevenson MA, Smith BD, Wilson LD, Richardson PG: Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. Journal of Clinical Oncology, 23:3138-3140, 2005
  15. Smith BD, Lally BZ, Haffty BG, Wilson LD: PET and sentinel node biopsy reduce the rate of elective neck dissection A hypothesis still in need of validation. Journal of Clinical Oncology 23:2874-2875, 2005.
  16. Wilson LD, Smith BD. Eosinophilia: Outcomes and bias. Journal of the American Academy of Dermatology 53:183, 2005.
  17. Housman D. Wilson LD, Smith BD: Merkel cell carcinoma: improved outcome with the addition of adjuvant therapy. Journal of Clinical Oncology 23:7236-7237, 2005.
  18. Smith BD: Indications for post-mastectomy radiation in older women. Women’s Oncology Review. In press.
  19. Wilson LD, Jones GW, Smith BD. Cutaneous lymphomas-radiotherapeutic strategies. Front Radiat Ther Oncol. 2006;39:1-15.
  20. Smith GL, Smith BD, Haffty BG. Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2006 May 31; Related Articles
  21. Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006 May 17;98(10):681-90. Related Articles
  22. Smith BD, Haffty BG, Buchholz TA, Smith GL, Galusha DH, Bekelman JE, Gross CP. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006;98:1302-10.
  23. Wilson LD, Smith BD. Primary cutaneous B-cell lymphoma. J Clin Oncol. 2006 Aug 20;24(24):4041
  24. Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., and Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18: 7016-7025, 1999.
  25. Harvey, S., Decker, R. H., Dai, Y., Schaeffer, G., Tang, L., Kramer, L., Dent, P., and Grant, S. Interactions Between 2-Fluoroadenine 9-β-D-Arabinofuranoside and the Kinase Inhibitor UCN-01 in Human Leukemia and Lymphoma. Clin. Cancer Res., 2001 Feb; 7(2):320-330.
  26. Cartee, L., Wang, Z., Decker, R. H., Chellappan, S. P., Hirsch, K. G., Sankala, H. M., Dent, P., and Grant, S. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Disrupts PMA-Induced Differentiation and CDKI Expression While Enhancing Apoptosis in Human Myeloid Leukemia Cells. Cancer Res., 2001 Mar 15; 61(6):2583-91.
  27. Decker, R.H., Dai, Y., and Grant, S., The Cyclin-Dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Human Leukemia Cells (U937) Through the Mitochondrial Rather than the Receptor-mediated Pathway. Cell Death Diff., 2001 July: 8(7):715-24.
  28. Quiao, L., Studer, E., Leach, K., McKinstry, R.,Gupta S., Decker, R.H., Kukreja, R., Valerie, K., Nagarkatti, P., El Deiry, W., Molkentin, J., Schmidt-Ullrich, R., Fisher, P.B., Grant, S., Hylemon, P.B., Dent, P., Deoxycholic acid (dca) causes ligand-independent activation of epidermal growth factor receptor (egfr) and fas receptor in primary hepatocytes: inhibition of egfr/mitogen activated protein kinase-signaling module enhances dca-induced apoptosis. Molecular Biology of the Cell, 2001 September; 12(9):2629-45.
  29. Decker R.H., Tang, L., Wang, S., and Grant, S., Flavopiridol-Induced Apoptosis in Human Leukemia Cells Circumvents Bcl-2-Mediated Resistance in a Manner Dependent upon the N-Terminal Phosphorylation Loop. Cancer Biology and Therapy, 2002 Mar-Apr;1(2):136-44.
  30. McKinstry R., Qiao L., Yacoub A., Dai Y., Decker R.H., Holt S., Hagan M.P., Grant S.,Dent P. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther. 2002 May-Jun;1(3):243-53.
  31. Decker R.H., Levin J., Kramer L.B., Dai Y., Grant S., Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. Biochem Pharmacol. 2003 Jun 15;65(12):1997-2008.
  32. Decker, RH, Tanoue, LT, Colasanto, JM, Detterbeck, FC, Wilson, LD. The Evaluation and Definitive Management of Medically Inoperable Non-Small Cell Lung Cancer. Oncology (Williston Park). 2006 Jun;20(7):727-36.
  33. Decker RH, Tanoue LT, Colasanto JM, Detterbeck FD, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology (Williston Park). 2006 Jul;20(8):899-905
  34. Decker RH, Wilson LD. Role of radiotherapy in the management of merkel cell carcinoma of the skin.  Journal of the National Comprehensive Cancer Network 2006 Aug;4(7):713-8.
  35. Chang B.W., Kim D.H., Kowalski D.P., Burleson J.A., Son Y.H., Wilson L.D., Haffty B.G.: Prognostic significance of COX-2 in oropharyngeal squamous cell carcinoma. Clinical Cancer Research 10: 1678-1684, 2004.
  36. Kim S, Rimm D, Carter D, Khan A, Parisot N, Franco MA, Bale A, Haffty BG. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. Breast J 9:167-74, 2003
  37. Lally BE, Colasanto JM, Fischer JJ, Knisely JP. Is there an optimal hemoglobin level for patients with glioblastoma multiforme Cancer J. 10:391-6, 2004.
  38. Lally BE, Haffty BG, Moran MS, Colasanto JM, Higgins SA. Management of suspicious or indeterminate calcifications and impact on local control. Cancer 2005;103:2236-40.
  39. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, and Wilson LD. The Impact of Post-operative Radiotherapy for Patients with Stage II or Stage III Non-small Cell Lung Cancer Utilizing the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 2006 Jul 1;24(19):2998-3006.
  40. Rosenberg MM, Blitzblau RC, Olsen DP, Jacob MH. Regulatory mechanisms that govern nicotinic synapse formation in neurons. J Neurobiol. 2002;53(4):542-55.
  41. Chen W, Aoki C, Mahadomrongkul V, Gruber CE, Wang GJ, Blitzblau R, Irwin N, Rosenberg PA. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J Neurosci. 2002;22(6):2142-52.
  42. Temburni MK, Blitzblau RC, Jacob MH. Related Articles, Links Receptor targeting and heterogeneity at interneuronal nicotinic cholinergic synapses in vivo. J Physiol. 2000;525:21-9.
  43. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E. NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000;20(23):8831-7.
  44. Blitzblau R, Gupta S, Djali S, Robinson MB, Rosenberg PA. The glutamate transport inhibitor L-trans-pyrrolidine-2,4-dicarboxylate indirectly evokes NMDA receptor mediated neurotoxicity in rat cortical cultures. Eur J Neurosci. 1996;8(9):1840-52.
  45. Speliotes EK, Hartnett KA, Blitzblau RC, Aizenman E, Rosenberg PA. Comparison of the potency of competitive NMDA antagonists against the neurotoxicity of glutamate and NMDA. J Neurochem. 1994;63(3):879-85.
  46. Yu JB, Shiao SL, Knisely JP.  A dosimetric evaluation of conventional helmet field irradiation versus two-field intensity-modulated radiotherapy technique.
    Int J Radiat Oncol Biol Phys. 2007;68:621-31.
  47. Wilson LD, Yu JB, Haffty BG. National Residency Matching Program (NRMP) results for radiation oncology: 2007 update.  Int J Radiat Oncol Biol Phys. 2007;69:326-7.
  48. Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of Primary Cutaneous Cd30+ Anaplastic Large-Cell Lymphoma with Radiation Therapy.  Int J Radiat Oncol Biol Phys. 2007 .
  49. Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database.  J Clin Oncol. 2008;26:1483-8.

Resident Textbook Chapters

  1. Wilson LD, Decker RH. Cutaneous Malignancies in Haffty BG, Wilson LD (ed):
    Handbook of Radiation Oncology, First Edition. Boston, MA, Jones and Bartlett,
    2008.
  2. Smith BD, Haffty BG: Prognostic factors in Head and Neck Cancer, in Harrison LB, Sessions RB, Hong WK (ed): Head and Neck Cancer: A Multidisciplinary Approach, Second Edition. New York, NY, Lippincott Williams and Wilkins, 2003, pp 49-73
  3. Tangir J, Smith B, Higgins SA, Schwartz PE: Therapy for Gynecologic Neoplasms, in Lobo RA (ed): Obstetrics and Gynecology—2003, 1 st Edition, New York, NY, Castle Connolly Graduate Medical Publishing, 2003, pp 1-30
  4. Smith BD, Jones G, Wilson LD: Mycosis Fungoides, in Gunderson LL, Tepper JE (ed): Clinical Radiation Oncology, Second Edition. Philadelphia, PA, Churchill Livingstone, 2007.
  5. Decker R., Wilson, L.D. Radiation, Fibrosis and the Treatment of Disorders Related to Scar Formation, 2006.

Resident Presentations at National/International Meetings

  1. Lloyd S, Ross DA, Wilson LD, Decker RH. Clinical and Pathologic Factors Predicting Nodal Metastasis in Minor Salivary Gland Cancer. Oral Presentation, American Radium Society Annual Meeting, May 2008, Laguna Niguel, California.One of 8 papers accepted for an American radium Society travel grant.
  2. Castrucci W, Gross C, Chiang V, Knisely J. A survey of treating physicians regarding the use of stereotactic radiosurgery alone for cranial oligometastases. Oral presentation, American Radium Society Annual Meeting, May 2008, Laguna Niguel, California.
  3. Urdaneta AI, Yu JB, Wilson LD. Primary Tracheal Carcinoma: Adenoid Cystic Carcinomas Have a Much Improved Prognosis Compared to Squamous Cell Carcinoma - An Analysis of the NCI SEER Database. Oral presentation, American Radium Society Annual Meeting, May 2008, Laguna Niguel, California.
  4. Yu JB, Wilson LD, Dasgupta T, Castrucci WA, Weidhaas JB. Post-Mastectomy Radiation Therapy for Node-Negative, Locally Advanced Breast Cancer After Modified Radical Mastectomy: Analysis of the NCI Surveillance, Epidemiology, and End Results Database. Oral presentation, American Radium Society Annual Meeting, May 2008, Laguna Niguel, California. One of 4 manuscripts selected for the Young Oncologist Essay Award.
  5. Roberts K.B., Blitzblau R.C., Wilson L.D.: Characterization of Non-Gastric MALT Lymphomas Identified in the SEER Database. The 49th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, Los Angeles, CA. October, 2007. Poster presentation.
  6. Blitzblau R.C., Wilson L.D., Yu J.W., Roberts K.B.: Gastric MALT Lymphomas Identified in the SEER Database. The 49th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, Los Angeles, CA. October, 2007. Poster presentation.
  7. Yu J.B., Blitzblau R.C., Decker R.H, Housman D.M., Wilson L.D.: Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Stage IE Primary CD30+ Cutaneous T-Cell Lymphoma (PCCTCL). The 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Los Angeles, CA. October, 2007. Poster presentation.
  8. Patel S.C., Yu J.B., Decker R.H., Blitzblau R.C., Housman D.M., Wilson L.D.: Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Microcystic Adnexal Carcinoma (Sclerosing Sweat Duct Carcinoma) of the Skin. The 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Los Angeles, CA. October, 2007. Poster presentation.
  9. Yu JB, Anderson NS, Decker RH, Blitzblau RC, Housman DM, Wilson LD. NCI Surveillance Epidemiology and End Results (SEER) Analysis of Sebaceous Carcinoma of the Skin. Oral Presentation, Annual Meeting of the Radiological Society of North America, November 2007, Chicago, IL.
  10. Decker RH, Smith BD, Wilson LD, Knisely JP. Adjuvant radiation is associated with improved overall survival in high risk pancreatic adenocarcinoma.  Oral Presentation, Annual Meeting of the American Radium Society, May 2007, Amsterdam, Netherlands. One of six presentations selected for the American Radium Society Travel Grant 2007.
  11. Chang B, Beardsley D, Piguet N, McNamara J and Roberts KB. Low-dose radiotherapy is an effective treatment for Kasabach-Merritt syndrome. Poster presentation, Annual meeting of the American Radium Society, May 2007, Amsterdam, Netherlands.
  12. Yu JB, Khan AM, Reavely MM, Jones GW, Wilson LD. Patient Perspectives Regarding The Value Of Total Skin Electron Beam Therapy For Cutaneous T-Cell Lymphoma / Mycosis Fungoides - A Pilot Study. Poster Presentation, Annual Meeting of the American Radium Society, May 2007, Amsterdam, Netherlands.
  13. Yu JB, Wilson LD. Treatment of Primary Cutaneous CD 30+ Anaplastic Large T-Cell Lymphoma with Localized Radiation Therapy. Oral Presentation, Annual Meeting of the American Radium Society, May 2007, Amsterdam, Netherlands.
  14. Yu JB, Knisely JP. Evaluation of standard whole brain radiotherapy versus IMRT dosimetry. Poster presentation, American Society for Therapeutic Radiology and Oncology 2006 Annual Meeting, November, 2006, Philadelphia, PA.
  15. Smith BD, Carter D, Sasaki CT, Haffty BG. Vascular endothelial growth factor protein levels are an independent predictor of poor outcome in oral cavity and oropharyngeal squamous cell carcinoma. Poster Presentation, American Society for Therapeutic Radiology and Oncology 1999 Annual Meeting, November 2, 1999, San Antonio, TX.
  16. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, Haffty BG. The prognostic value of molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Oral Presentation, 5 th International Conference on Head and Neck Cancer, August 1, 2000, San Francisco, CA.
  17. Smith BD, Smith GL, Heald PW, Cooper D, Wilson LD. Effectiveness of radiotherapy as initial treatment for cutaneous B-cell lymphoma. Poster Discussion Section - Lymphoma, American Society for Therapeutic Radiology and Oncology 2003 Annual Meeting, October 20, 2003, Salt Lake City, UT.
  18. Smith BD, Smith GL, Haffty BG. The importance of number of involved regional lymph nodes in predicting survival benefit from postmastectomy radiation: analysis of a large, population-based cohort of women with T1-2 N+ breast cancer. Oral presentation, Annual Meeting of the American Radium Society, May 2, 2004, Napa Valley, CA.
  19. Smith BD, Smith GL, Cooper DL, Wilson LD. Cutaneous B-Cell Lymphoma: An emerging clinical entity. Oral Presentation, American Society for Therapeutic Radiology and Oncology 2004 Annual Meeting, October 6, 2004, Atlanta, GA.
  20. Decker, RH. Endogenous Expression of the Tumor Suppressor p53 Enhances Ara-C-Induced Apoptosis in Human Leukemia Cells (U937). American Society of Hematology Annual Meeting, New Orleans, Louisiana; 1999. Oral Presentations
  21. Decker RH. The Role of Bcl-2 in Flavopiridol-Induced Apoptosis. M.D., Ph.D. Student Conference, Aspen, Colorado, 1999. Poster Presentation
  22. Decker, RH. Flavopiridol Overcomes Bcl-2-Mediated Resistance to Apoptosis. AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics, Washington, D.C., 1999. Poster Presentation
  23. Decker RH. Endogenous Expression of the Tumor Suppressor p53 Enhances Ara-C-Induced Apoptosis in Human Leukemia Cells (U937). American Association for Cancer Research Annual Meeting, San Francisco, California, 2000. Poster Presentation
  24. Decker, RH. Flavopiridol Induces Apoptosis in Human Leukemia Cells via the Mitochondrial Pathway and Circumvents Bcl-2-Mediated Resistance in a Manner Dependent upon the N-Terminal Loop Domain. American Society of Hematology Annual Meeting, San Francisco, California; 2000. Poster Presentation
  25. Decker, RH.Endogenous Expression of the Tumor Suppressor p53 Enhances Byrostatin-1-Induced Differentiation in Human Leukemia Cells (U937). American Association for Cancer Research Annual Meeting, New Orleans, Louisiana; 2001. Poster Presentation
  26. Chang B., Beale R., Richman D. and Agius, M. Pathogenicity of monoclonal antibodies to synapse-localized proteins other than the acetylcholine receptor in myasthenia gravis. Platform presentation, Myasthenia Gravis Foundation of America Scientific Session, 2000.